Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Scientists Discover New Strain Of HIV Closely Related To Simian Virus
Scientists have discovered a new strain of HIV in a 62-year-old woman from Cameroon that "differs from the three known strains ò€¦ and appears to be closely related to a form of simian virus recently discovered in wild gorillas" according to a study in today"s edition of the journal Nature Medicine, AP/Washington Times reports. The study was funded by the NIH and the Tietze Foundation (8/3). "The discovery of this novel HIV-1 lineage highlights the continuing need to watch closely for the emergence of new HIV variants, particularly in western central Africa, the origin of all existing HIV-1 groups," researchers note in the study (Reuters, 8/3). According to the AP/San Francisco Chronicle, the woman had no contact with gorillas or meat from wild animals and "currently shows no signs of AIDS and remains untreated, though she still carries the virus, the researchers said." The article adds, "How widespread this strain is remains to be determined. Researchers said it could be circulating unnoticed in Cameroon or elsewhere."

Thousands Of New Mexicans Could Lose Private Insurance, Study Shows
An estimated 428,000 residents in New Mexico could lose their private, employer-based coverage if Congress passes a House health reform bill, according to state-specific analysis of The American Affordable Health Choices Act of 2009 released this week by The Heritage Foundation.
News of the day
Xenophon Attacks South Australian Aged Care Nurses
Australian Nursing Federation (ANF) Federal Secretary Ged Kearney said comments made by Senator Nick Xenophon today display a lack of understanding of the award modernisation process and the benefits this process brings to nursing staff, employers and the aged care industry.
Medical Devices

PPD Confirms Takeda Receives FDA Complete Response For Alogliptin

PPD, Inc. (NASDAQ: PPDI) today announced that Takeda Pharmaceutical Company Limited issued a news release reporting that Takeda Global Research & Development Center, Inc., its wholly-owned U.S. subsidiary, has received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding its new drug application (NDA) for alogliptin. PPD is partnering with Takeda to develop alogliptin, a selective dipeptidyl peptidase IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise. In recent months, the FDA and Takeda have been in discussions about conducting an additional cardiovascular study for alogliptin. PPD announced on March 6, 2009, that the FDA had informed Takeda that, although the alogliptin NDA was filed prior to the release of the December 2008 FDA guidance titled, "Guidance for Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes," the FDA did not believe that the amount of existing alogliptin clinical data was sufficient to meet certain statistical requirements outlined in that guidance. The FDA has asked Takeda to conduct an additional cardiovascular safety trial that satisfies the December 2008 FDA guidance. PPD


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009